Morgan Stanley Reiterates Overweight Rating on Mirum Pharmaceuticals (MIRM) amid study enrollment, screening completion

Morgan Stanley analyst Michael E Ulz reiterated an Overweight rating and $130.00 price target on Mirum Pharmaceuticals (NASDAQ: MIRM)

The analyst commented, "Earlier today, Mirum announced completion of enrollment in the Ph3 AZURE 1 study and completion of screening in the Ph3 AZURE 4 study, both evaluating brelovitug for the treatment of chronic hepatitis delta virus (HDV) infection... Overall, we are encouraged by ongoing progress confirming timelines for key HDV data readouts later this year. As a reminder, beyond HDV, we expect multiple additional catalysts in 2026 including Ph3 data for volixibat in PSC 2Q26 and Ph3 data form the EXPAND study of Livmarli in cholestatic pruritus 4Q26, which should drive continued momentum."

For an analyst ratings summary and ratings history on Mirum Pharmaceuticals click here. For more ratings news on Mirum Pharmaceuticals click here.

Shares of Mirum Pharmaceuticals closed at $93.04 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Freedom Broker Upgrades Lifeway Foods (LWAY) to Buy
• Mosaic sets pricing for tender offers on up to $1.4B in debt